Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | GLA | P06280 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | ME2 | P23368 | 1/20 | 0.55 |
| ▸ | ME1 | P48163 | 1/20 | 0.55 |
| ▸ | ME3 | Q16798 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29379734 | 1.00 | GPR35 (0.61) | GPR35POLBHSD17B10CYP1A2MEN1 | |
| SCHEMBL83897 | 0.86 | CYP1A2 (0.61) | GPR35POLBHSD17B10CYP1A2MEN1 | |
| SCHEMBL770722 | 0.82 | CYP1A2 (0.70) | GPR35POLBHSD17B10CYP1A2MEN1 | |
| SCHEMBL28860671 | 0.82 | SLC37A4 (0.51) | GPR35POLBHSD17B10CYP1A2MEN1 | |
| SCHEMBL31149178 | 0.80 | CYP1A2 (0.62) | GPR35POLBHSD17B10CYP1A2MEN1 | |
| SCHEMBL245378 | 0.80 | CYP1A2 (0.62) | GPR35POLBHSD17B10CYP1A2MEN1 | |
| SCHEMBL7107682 | 0.79 | KAT8 (0.51) | HSD17B10CYP1A2MEN1KMT2ACYP2C19 | |
| SCHEMBL10684176 | 0.79 | KAT8 (0.51) | HSD17B10CYP1A2MEN1KMT2ACYP2C19 | |
| SCHEMBL27857954 | 0.77 | MEN1 (0.58) | GPR35POLBHSD17B10CYP1A2MEN1 | |
| SCHEMBL1269455 | 0.77 | KMT2A (0.58) | GPR35POLBHSD17B10CYP1A2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582631-B2 | Methods of improving renal function | CHINOOK THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12521369-B2 | Methods of improving renal function | CHINOOK THERAPEUTICS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250352511-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | CHINOOK THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-12453781-B2 | Methods of treating cancer with a combination of an anti-VEGF antibody and an anti-tissue factor antibody-drug conjugate | GENMAB A/S (DK) | 2025-10-28 | — | — | US | disclosed |
| US-20250302982-A1 | METHODS OF TREATING CANCER WITH ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-10-02 | — | — | US | disclosed |
| US-20250295801-A1 | CD25 ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND USES THEREOF | SEAGEN INC. (US) | 2025-09-25 | — | — | US | disclosed |
| US-12421312-B2 | Anti-PD-L1 antibodies and antibody-drug conjugates | SEAGEN INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250281454-A1 | METHODS OF IMPROVING RENAL FUNCTION | CHINOOK THERAPEUTICS, INC. | 2025-09-11 | — | — | US | disclosed |
| US-20250276076-A1 | ANTI-ALPP/ALPPL2 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | SEAGEN INC. (US) | 2025-09-04 | — | — | US | disclosed |
| US-20250242041-A1 | ANTI-AVB6 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | SEAGEN INC. (US) | 2025-07-31 | — | — | US | disclosed |
| EP-3768325-A1 | METHODS OF TREATING CANCER WITH A COMBINATION OF A PLATINUM-BASED AGENT AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE | Genmab A/S (DK) | 2021-01-27 | — | — | EP | disclosed |
| US-20210015939-A1 | METHODS OF TREATING CANCER WITH A COMBINATION OF A PLATINUM-BASED AGENT AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2021-01-21 | — | — | US | disclosed |
| EP-3703757-A1 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER | Genmab A/S (DK) | 2020-09-09 | — | — | EP | disclosed |
| WO-2020163225-A1 | ANTI-CD228 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| US-20200246479-A1 | ANTI-CD228 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | SEAGEN INC. | 2020-08-06 | — | — | US | disclosed |
| WO-2020037024-A1 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER | GENMAB A/S (DK) | 2020-02-20 | — | — | WO | disclosed |
| WO-2019183253-A1 | METHODS OF TREATING CANCER WITH A COMBINATION OF A PLATINUM-BASED AGENT AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE | GENMAB A/S (DK) | 2019-09-26 | — | — | WO | disclosed |
| US-7678773-B2 | Salts of avermectins substituted in the 4″-position and having pesticidal properties | MERIAL LIMITED (US) | 2010-03-16 | — | — | US | disclosed |
| US-20060105971-A1 | Salts of avermectins substituted in the 4\"-position and having pesticidal properties | SYNGENTA CROP PROTECTION, INC. | 2006-05-18 | — | — | US | disclosed |
| US-20050090458-A1 | Salts of avermectins substituted in the 4\"-position and having pesticidal properties | SYNGENTA CROP PROTECTION, INC. | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421312-B2 | Anti-PD-L1 antibodies and antibody-drug conjugates | PDCD1LG2, CD274, PDCD1 | GPR35 4390/4885POLB 2753/4885HSD17B10 2179/4885 |
| US-20250276076-A1 | ANTI-ALPP/ALPPL2 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | ALPP, ALPG, HLA-A | GPR35 3549/4885POLB 710/4885HSD17B10 2561/4885 |
| US-20250281454-A1 | METHODS OF IMPROVING RENAL FUNCTION | GLS, ATP6V1B1, FABP3 | GPR35 3295/4885POLB 3444/4885HSD17B10 1388/4885 |
| US-20250295801-A1 | CD25 ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND USES THEREOF | IL2RA, CD4, IL2 | GPR35 1127/4885POLB 4302/4885HSD17B10 2695/4885 |
| US-12453781-B2 | Methods of treating cancer with a combination of an anti-VEGF antibody and an anti-tissue factor antibody-drug conjugate | VEGFA, F3, FLT4 | GPR35 2535/4885POLB 3114/4885HSD17B10 4371/4885 |
| US-20060105971-A1 | Salts of avermectins substituted in the 4\"-position and having pesticidal properties | PTMS, HCN3, HCN1 | GPR35 4329/4885POLB 4434/4885HSD17B10 2075/4885 |
| US-20050090458-A1 | Salts of avermectins substituted in the 4\"-position and having pesticidal properties | PTMS, HCN3, HCN1 | GPR35 4250/4885POLB 4415/4885HSD17B10 2097/4885 |
| US-20250242041-A1 | ANTI-AVB6 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | ITGB6, ITGA6, ITGAV | GPR35 4414/4885POLB 1976/4885HSD17B10 2477/4885 |
| US-20250352511-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | REN, AGT, FRS2 | GPR35 738/4885POLB 4791/4885HSD17B10 2746/4885 |
| US-20250302982-A1 | METHODS OF TREATING CANCER WITH ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES | ADAMTS13, ADAMTS4, ADAMTS5 | GPR35 4137/4885POLB 3090/4885HSD17B10 3894/4885 |
| US-20200246479-A1 | ANTI-CD228 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | CD2, CD22, CD2BP2 | GPR35 1477/4885POLB 4821/4885HSD17B10 3036/4885 |
| US-12582631-B2 | Methods of improving renal function | LGALS1, LGALS9, REN | GPR35 1861/4885POLB 4882/4885HSD17B10 2111/4885 |
| US-20210015939-A1 | METHODS OF TREATING CANCER WITH A COMBINATION OF A PLATINUM-BASED AGENT AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE | F3, TFPI, ADAMTS13 | GPR35 2541/4885POLB 3148/4885HSD17B10 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.